A highly X-ray sensitive iridium prodrug for visualized tumor radiochemotherapy. Issue 15 (1st April 2020)

• Record Type: Journal Article
• Authors: Zhao, Zhennan; Gao, Pan; Ma, Li; Chen, Tianfeng
• Is Part Of: Chemical science. Volume 11:Issue 15(2020)
• Page Start: 3780
• Page End: 3789
• Publication Date: 2020-04-01
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d0sc00862a
• Languages: English
• ISSNs: 2041-6520

Abstract

Abstract : A highly X-ray sensitive molecular prodrug, Ir-NB, was reported for visualized tumor radiochemotherapy. To our knowledge, the sensitivity enhancement ratio of the prodrug is the highest among the reported radiotherapy metal complexes drugs. Abstract : Concomitant treatment of radiotherapy and chemotherapy is widely used in cancer therapy. The search for highly efficient radiochemotherapy drugs for tumor targeting therapy under image-guiding is of considerable interest. Herein we report an Ir-based prodrug Ir-NB with high sensitization efficiency for in vivo tumor microenvironment responsive cancer-targeted bioimaging radiochemotherapy. To the best of our knowledge, the sensitivity enhancement ratio (SER) of the Ir-NB prodrug is the highest among those reported for radiotherapy metal complex drugs. From detailed action mechanism study, we provide evidence that the prodrug is effectively suppresses the tumor growth through inducing mitochondrial dysfunction, and eventually amplifies the apoptotic signal pathway. This study provides an approach for the development of cancer theranostic agents for tumor radiotherapy.